Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Gothenburg, February 7, 2023 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commercially available platform iTANK, today announced that it has recruited LifeSci Consulting as transaction advisor to assist the company in evaluating a variety of strategic partnering initiatives.Elicera’s collaboration with LifeSci Consulting is a long-term investment that follows an increase in third-